Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - TG THERAPEUTICS, INC. | v439471_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report
(Date of earliest event reported): May 5, 2017
TG
Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2
Gansevoort Street, 9th Floor
New
York, New York 10014
(Address of
Principal Executive Offices)
(212)
554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities
Act.
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act.
☐
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
Item
2.02. Results of Operations and Financial Condition.
On May 5, 2017, TG
Therapeutics, Inc. TG Therapeutics,
Inc. (“TG” or the “Company”) issued a press
release announcing results of operations for the first quarter
ended March 31, 2017. TG also announced that on Friday, May 5, 2017
at 8:30am ET, TG would host an investor conference call during
which the Company would provide a brief overview of its first
quarter financial results and provide a business outlook for the
remainder of 2017. A copy of such press release is being furnished
as Exhibit 99.1.
Item
9.01 Financial Statements And Exhibits.
(d)
Exhibits.
99.1
Press release
issued by TG Therapeutics, Inc., dated May 5, 2017.
- 2 -
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TG Therapeutics,
Inc.
(Registrant)
By: /s/ Sean A. Power
Sean A. Power
Chief Financial Officer
Date: May 5,
2017
- 3 -
INDEX TO EXHIBITS
Exhibit
Number
Description
99.1
Press release issued by TG Therapeutics, Inc., dated
May 5, 2017.
- 4 -